The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

References

• Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59(1):110-18
   PubMed Web of Science ®Google Scholar
• Burrell RA, McGranahan N, Bartek J, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501(7467):338-45
   PubMed Web of Science ®Google Scholar
• Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14(3):275-91
   PubMed Web of Science ®Google Scholar
• Dhawan P, Ahmad R, Srivastava AS, et al. Cancer stem cells and colorectal cancer: an overview. Curr Top Med Chem 2011;11(13):1592-8
   PubMedGoogle Scholar
• Garza-Treviño EN, Said-Fernández SL, Martínez-Rodríguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int 2015;15(1):2
   PubMedGoogle Scholar
• Cabrera MC, Hollingsworth RE, Hurt EM. Cancer stem cell plasticity and tumor hierarchy. World J Stem Cells 2015;7(1):27-36
   PubMed Web of Science ®Google Scholar
• Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23(3):450-7
   PubMed Web of Science ®Google Scholar
• Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14(21):6751-60
   PubMed Web of Science ®Google Scholar
• Todaro M, Gaggianesi M, Catalano V, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014;14(3):342-56
   PubMed Web of Science ®Google Scholar
• Kimura Y, Goi T, Nakazawa T, et al. CD44variant exon 9 plays an important role in colon cancer initiating cells. Oncotarget 2013;4(5):785-91
   PubMedGoogle Scholar
• Katoh S, Goi T, Naruse T, et al. Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Anticancer Res 2015;35(1):239-44
   PubMed Web of Science ®Google Scholar
• Pereira L, Mariadason JM, Hannan RD, et al. Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. Front Oncol 2015;5:13
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331(6024):1559-64
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13(3):920-8
   PubMed Web of Science ®Google Scholar
• Zheng S, Lin HK, Lu B, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 2011;13(1):203-13
   PubMed Web of Science ®Google Scholar
• Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010;107(43):18392-7
   PubMed Web of Science ®Google Scholar
• Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014;134(3):552-62
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Salazar R, Tabernero J. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. Am Soc Clin Oncol Educ Book 2014;91-9
   PubMedGoogle Scholar
• Ombrato L, Malanchi I. The EMT universe: space between cancer cell dissemination and metastasis initiation. Crit Rev Oncog 2014;19(5):349-61
   PubMedGoogle Scholar
• Shelygin YA, Pospekhova NI, Shubin VP, et al. Epithelial-mesenchymal transition and somatic alteration in colorectal cancer with and without peritoneal carcinomatosis. Biomed Res Int 2014;2014:629496
   PubMedGoogle Scholar
• Lou XL, Deng J, Deng H, et al. Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review). Biomed Rep 2014;2(3):331-4
   PubMedGoogle Scholar
• Shang Y, Cai X, Fan D. Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets 2013;13(9):915-29
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011;11(9):777-92
   PubMed Web of Science ®Google Scholar
• Lim SH, Becker TM, Chua W, et al. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol 2014;67(10):848-53
   PubMedGoogle Scholar
• Shiota M, Bishop JL, Nip KM, et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013;73(10):3109-19
   PubMed Web of Science ®Google Scholar
• Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014;158(5):1110-22
   PubMed Web of Science ®Google Scholar
• Divella R, Daniele A, Abbate I, et al. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer. Cancer Causes Control 2014;25(11):1531-4
   PubMedGoogle Scholar
• Harouaka RA, Zhou MD, Yeh YT, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem 2014;60(2):323-33
   PubMed Web of Science ®Google Scholar
• Parsons BL, Myers MB. Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov Med 2013;15(83):259-67
   PubMed Web of Science ®Google Scholar
• Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014;4(11):1269-80
   PubMed Web of Science ®Google Scholar
• Mao C, Wu XY, Yang ZY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep 2015;5:8065
   PubMed Web of Science ®Google Scholar
• Dieterle CP, Conzelmann M, Linnemann U, et al. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin Cancer Res 2004;10(2):641-50
   PubMedGoogle Scholar
• Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 2014;15(8):449
   PubMed Web of Science ®Google Scholar
• Raimondi C, Nicolazzo C, Gradilone A, et al. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol Ther 2014;15(5):496-503
   PubMed Web of Science ®Google Scholar
• Desitter I, Guerrouahen BS, Benali-Furet N, et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 2011;31(2):427-41
   PubMed Web of Science ®Google Scholar
• Yusa A, Toneri M, Masuda T, et al. Development of a new rapid isolation device for circulating tumor cells (CTCs) using 3D palladium filter and its application for genetic analysis. PLoS One 2014;9(2):e88821
   Google Scholar
• Huang T, Jia CP, Jun-Yang et al. Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip. Biosens Bioelectron 2014;51:213-18
   PubMedGoogle Scholar
• Tang Y, Shi J, Li S, et al. Microfluidic device with integrated microfilter of conical-shaped holes for high efficiency and high purity capture of circulating tumor cells. Sci Rep 2014;4:6052
   PubMed Web of Science ®Google Scholar
• Zhou MD, Hao S, Williams AJ, et al. Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells. Sci Rep 2014;4:7392
   PubMed Web of Science ®Google Scholar
• Welti J, Loges S, Dimmeler S, et al. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123(8):3190-200
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lambrechts D, Prenen H, et al. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol 2011;29(1):1-4
   PubMed Web of Science ®Google Scholar
• Manzoni M, Comolli G, Torchio M, et al. Circulating Endothelial Cells and Their Subpopulations: Role as Predictive Biomarkers in Antiangiogenic Therapy for Colorectal Cancer. Clin Colorectal Cancer 2015;14(1):11-17
   PubMed Web of Science ®Google Scholar
• Cayrefourcq L, Mazard T, Joosse S, et al. C.Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 2015;75(5):892-901
   PubMed Web of Science ®Google Scholar
• Li J, Sharkey CC, Huang D, et al. Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. 2015;8(1):137-50
   Google Scholar